CompletedPHASE1, PHASE2NCT00527566

Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome

Studying Vasculitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Brigham and Women's Hospital
Principal Investigator
Michael Wechsler, MD
Brigham and Women's Hospital
Intervention
Mepolizumab(biological)
Enrollment
10 enrolled
Eligibility
19 years · All sexes
Timeline
20072009

Study locations (1)

Collaborators

GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00527566 on ClinicalTrials.gov

Other trials for Vasculitis

Additional recruiting or active studies for the same condition.

See all trials for Vasculitis

← Back to all trials